Shots:
The company initiates a PK study to evaluate PK, safety, and tolerability of AVT03 (denosumab) vs Prolia and Xgeva in healthy adult male patients with bone disease
Prolia is indicated for the treatment of osteoporosis in postmenopausal and to treat bone loss in adult men and women who are at increased risk of fracture. Xgeva is indicated to prevent skeletal fractures in patients with cancer incl. bone & for giant cell tumors in bone
The capabilities of Alvotech’s biosimilars platform are demonstrated by the quick progress in the development of the product portfolio. In the EU and Canada, the company has launched AVT02 (adalimumab), a biosimilar to Humira
Ref: GlobalNewswire | Image: Alvotech
